Antibody-Drug Conjugates May Represent the Future of HER2-Low Breast Cancer Treatment

Via Peters

Emerging data with novel antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan-nxki (Enhertu), vic-trastuzumab duocarmazine, and disitamab vedotin (Aidixi) are showing encouraging activity in HER2-low breast cancer. Paolo Tarantino, MD, said this data suggests that the classification of HER2 should go beyond merely positive or negative. “In the future, we will […]